D.A. Davidson & Co’s Neurocrine Biosciences NBIX Stock Holding History

D.A. Davidson & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15	Closed	–	–	2251
2015 Q2	$0	Buy	+15	New	+$636	﹤0.01%	2262

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.A. Davidson & Co's NBIX Position: Q3 2015 in Review

D.A. Davidson & Co sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 15 shares.

D.A. Davidson & Co first reported a position in NBIX in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 207 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

D.A. Davidson & Co reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
D.A. Davidson & Co sold 15 Neurocrine Biosciences shares in Q3 2015.
D.A. Davidson & Co first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 1 quarter.
D.A. Davidson & Co's Neurocrine Biosciences position peaked at $0 in Q2 2015.
207 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on D.A. Davidson & Co's 13F filing for Q3 2015, filed 13 Nov 2015.